Dr Reddy's Labs Q4 Results: Cons PAT jumps 22% to Rs 1,594 crore; Rs 8 per share dividend announced

Synopsis

Dr Reddy's Labs Q4 Results: Dr Reddy's Laboratories connected Friday reported a consolidated nett net maturation of 22% to Rs 1,594 crore successful Q4FY25 versus Rs 1,307 crore reported successful the twelvemonth agone period.

Dr Reddy's Laboratories connected Friday reported a consolidated nett net maturation of 22% to Rs 1,594 crore successful Q4FY25 versus Rs 1,307 crore reported successful the twelvemonth agone period.

The pharma major's gross from operations successful the March-ended 4th stood astatine Rs 8,506 crore, which was up 20% versus Rs 7,083 crore successful the corresponding 4th of the past fiscal year.

The institution recommended a last dividend of Rs 8 per equity stock for the fiscal twelvemonth 2024-25.

The nett aft taxation (PAT) was up 13% connected the quarter-on-quarter ground versus Rs 1,413 crore successful Q3FY25. All profits are attributable to equity holders of the company.

The topline surged 1.8% sequentially implicit Rs 8,359 crore reported successful the October-December 4th of FY25.

In its planetary generics business, North America contributed gross of Rs 3,559 crore, witnessing a 9% growth. The European concern gross jumped 145% to Rs 1,275 crore. This included revenues from the acquired NRT concern of Rs 597 crore for Q4FY25. The India concern gross grew 16% YoY to Rs 1,305 crore from Rs 1,126 crore successful Q4FY24.

Company's Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood astatine Rs 2,475 crore successful the 4th nether reappraisal which was 29% of the revenues.

The pharmaceutical services & Active Ingredients (PSAI) besides recorded a 16% YoY maturation astatine Rs 956 crore versus Rs 822 crore successful the twelvemonth agone period.

Management take

Commenting connected the results, Co-Chairman & MD, G V Prasad said that the institution achieved double-digit maturation crossed our businesses, driven by palmy merchandise launches, accrued revenues from cardinal products successful the US and the integration of the acquired NRT business. "We volition proceed to fortify and turn our halfway businesses done portfolio absorption and operational," helium said.

...moreless

...moreless